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OBJECTIVE—To test the hypothesis that free fatty acid
(FFA) and muscle glycogen modify exercise-induced regula-
tion of PDH (pyruvate dehydrogenase) in human skeletal
muscle through regulation of PDK4 expression.
RESEARCH DESIGN AND METHODS—On two occasions,
healthy male subjects lowered (by exercise) muscle glycogen in
one leg (LOW) relative to the contra-lateral leg (CON) the day
before the experimental day. On the experimental days, plasma
FFA was ensured normal or remained elevated by consuming
breakfast rich (low FFA) or poor (high FFA) in carbohydrate, 2 h
before performing 20 min of two-legged knee extensor exercise.
Vastus lateralis biopsies were obtained before and after exercise.
RESULTS—PDK4 protein content was 2.2- and 1.5-fold
higher in LOW than CON leg in high FFA and low FFA, respec-
tively, and the PDK4 protein content in the CON leg was
approximately twofold higher in high FFA than in low FFA. In all
conditions, exercise increased PDHa (PDH in the active form)
activity, resulting in similar levels in LOW leg in both trials and
CON leg in high FFA, but higher level in CON leg in low FFA.
PDHa activity was closely associated with the PDH-E1 phos-
phorylation level.
CONCLUSIONS—Muscle glycogen and plasma FFA attenuate
exercise-induced PDH regulation in human skeletal muscle in a
nonadditive manner. This might be through regulation of PDK4
expression. The activation of PDH by exercise independent of
changes in muscle glycogen or plasma FFA suggests that exer-
cise overrules FFA-mediated inhibition of PDH (i.e., carbohy-
drate oxidation), and this may thus be one mechanism behind the
health-promoting effects of exercise. Diabetes 59:26–32, 2010
I
nsulin resistance has been suggested to be associ-
ated with dysregulation of the pyruvate dehydroge-
nase complex in skeletal muscle, but the underlying
mechanism remains unclear (1–3). However, it has
been suggested that elevated plasma free fatty acid (FFA)
concentrations is the initial triggering event leading to
downregulation of PDH (pyruvate dehydrogenase) activity
and thus potentially contributing to insulin resistance (1).
The pyruvate dehydrogenase complex occupies a cen-
tral role in carbohydrate metabolism, catalyzing the ﬁrst
irreversible step in mitochondrial glucose metabolism, and
hence determines the fate of carbohydrates in skeletal
muscle metabolism (4). Regulation of PDH activity in
human skeletal muscle is believed mainly to be mediated
through changes in the phosphorylation state of site one
(Ser
293) and two (Ser
300) on the PDH-E1 subunit, where
dephosphorylation activates (5). The known regulatory
kinases and phosphatases include four isoforms of PDH
kinase (PDK1–4) and two PDH phosphatases (PDP1–2)
(6–8). Of these, PDK2, PDK4, and PDP1 are thought to be
the important isoforms in skeletal muscle (4,8,9).
Skeletal muscle PDH activity is affected by fasting,
high-fat diet, and exercise (4,10–13). Factors responsible
for this regulation have been suggested to include changes
in plasma FFA concentration (1,12,14), muscle glycogen
content (15–17), plasma insulin levels (14,18–20), and
intracellular Ca
2 concentration (21,22). Thus, regulation
of PDH seems to be under both local and systemic control
(17). Insulin activates PDH at least in part through down-
regulation of PDK4 expression as shown at the protein
level in rat skeletal muscle (14). Also based on ﬁndings in
rat skeletal muscle, plasma FFA is also believed to reduce
PDH activity through a peroxisome proliferator–activated
receptor (PPAR)-–mediated upregulation of PDK4 pro-
tein (14). Similarly, manipulation of the muscle glycogen
content in humans has indicated that lowering of muscle
glycogen upregulates PDK4 at the transcriptional and
mRNA level (15,16). As previously suggested, such a
glycogen-dependent regulation of gene expression may
take place through glycogen regulatory enzymes such as
protein phosphatase 1 (PP1) and glycogen synthase kinase
3 (GSK3), which are bound to the glycogen scaffold, but
released when the glycogen content decreases (15). How-
ever, in these studies, plasma FFA and muscle glycogen
were manipulated simultaneously, making it impossible to
discriminate between the role of muscle glycogen and
FFA.
Therefore, the aim of the present study was to test the
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FFA modify exercise-induced PDH regulation in human
skeletal muscle independent of each other, potentially
through regulation of PDK4 expression.
RESEARCH DESIGN AND METHODS
Eight healthy normally physical active male subjects with an average age of
26.5 years (range 22–31), weight 80.6 kg (60.4–99.8), and stature of 184.6 cm
(175–193) participated in the study. The average peak oxygen uptake of the
subjects was 51.8 ml O2  min
1  kg
1 (47.9–55).
The subjects were given both written and oral information about the
experimental protocol and procedures and were informed about any discom-
fort that might be associated with the experiment before they gave their
written consent. The study was performed according to the Declaration of
Helsinki and was approved by the Copenhagen and Frederiksberg Ethics
Committee, Denmark (H-C-2007-0085).
Experimental protocol. Approximately 2 weeks before the ﬁrst trial, peak
oxygen uptake and Wattmax of the subjects were determined by an incremen-
tal bicycle test. Furthermore, Wattmax during two-legged knee extensor
exercise was determined by an incremental test, with a starting resistance of
48–60 W and increasing the load by 12 W every 2 min. The maximal resistance
that could be sustained for 2 min was set as Wattmax.
Each subject completed two experimental trials, which consisted of
identical exercise protocols, but differed in the dietary protocol.
The subjects were instructed to eat food rich in carbohydrates 5 days
before a glycogen depletion protocol. Before reporting at the laboratory on the
day of glycogen depletion, the subjects consumed a prepackaged standardized
meal regulated to body weight and activity level (23), with 77% energy (%E)
carbohydrate, 10E% protein, and 13%E fat.
The day before each experimental trial, the subjects arrived at the
laboratory between 4:00 and 6:00 P.M. To reduce muscle glycogen in one leg,
the subjects performed a one-legged cycling exercise protocol, consisting of
20 min continuous cycling (10 min 65% Wattmax and 10 min 55% Wattmax)
followed by intermittent one-legged cycling as previously described (15). The
depletion leg was randomly selected. To lower glycogen stores in the liver,
and thus to minimize glycogen resynthesis, the subjects furthermore per-
formed 30 min of arm cycling. After the glycogen depletion, they were given
a dinner low in carbohydrates (1%E carbohydrate, 26%E protein, and 73%E
fat) to prevent muscle glycogen resynthesis.
On the experimental day (Fig. 1), the subjects arrived at the laboratory in
the morning 2 h after intake of a prepacked breakfast either high in fat (high
FFA) (3%E carbohydrate, 18%E protein, and 79%E fat) or high in carbohydrate
(low FFA) (74%E carbohydrate, 12E% protein, and 14%E fat). This breakfast
was the only difference between the trials and aimed at obtaining similar
insulin levels, whereas FFA levels were different in the two trials.
The two trials were separated by at least 10 days and were performed in
random order. A venous catheter was inserted in either v. cephalica or v.
mediana cubiti, and a resting blood sample was taken. Furthermore, two
incisions were made in the middle part of vastus lateralis of each leg under
local anesthesia (lidocaine), and a resting biopsy was obtained from the
glycogen depleted leg (LOW) and the nonexercised leg (CON) using the
percutaneous needle biopsy technique (24), with suction. Thereafter, the
subjects performed a two-legged knee extensor exercise bout at 75% Wattmax
for 10 min followed by 10 min at 65% Wattmax. Immediately at the end of the
20-min exercise period, a muscle biopsy was obtained simultaneously from
each leg through the prior made new incisions. Additional blood samples were
taken after 10 and 20 min of exercise. The work that each leg performed was
evaluated using strain gauge. The LOW and CON leg did an equal amount of
work in both trials.
Blood parameters. Plasma FFA was measured with a Wako FA kit (Wako
Chemical, Neuss, Germany) and an automatic spectrophotometer (Cobas
FARA 2; Roche Diagnostic, Basel, Switzerland). Plasma insulin was measured
with an insulin enzyme-linked immunosorbent assay (ELISA) kit (DakoCyto-
mation, Glostrup, Denmark).
Muscle glycogen. Muscle specimens were freeze-dried and dissected free of
blood, fat, and connective tissue under the microscope, and muscle glycogen
content was determined as glycosyl units after acid hydrolysis (25) using
an automatic spectrophotometer (Cobas FARA 2, Roche Diagnostic,
Switzerland).
Muscle lysate. Muscles pieces were homogenized in an ice-cold buffer (10%
glycerol, 20 mmol/l Na-pyrophosphate, 150 mmol/l NaCl, 50 mmol/l HEPES, 1%
NP-40, 20 mmol/l -glycerophosphate, 10 mmol/l NaF, 1 mmol/l EDTA, 1
mmol/l EGTA, 2 mmol/l phenylmethylsulfonyl ﬂuoride, 10 g/ml aprotinin, 10
g/ml leupeptin, 2 mmol/l Na3VO4, 3 mmol/l benzamidine, pH 7.5) for 20 s
using a polytron (PT 1200; Kinematica AG, Switzerland). Homogenates were
rotated end over end for1ha t4°C. Lysates were generated by centrifugation
(17,500g) for 20 min at 4°C. Protein content in lysates was measured by the
bicinchoninic acid method (Pierce, Rockford, IL).
SDS-PAGE and Western blotting. PDH-E1 and PDK4 protein expression
and phosphorylation of PDH-E1 site 1 and 2 were measured in muscle
samples by SDS-PAGE (Tris-HCl 10% gel, Bio-Rad, Denmark) and Western
blotting using PVDF membrane and semi-dry transfer. After the transfer, the
PVDF membrane was blocked overnight at 4°C (Tris-buffered saline with
Tween [TBST]  2% skim milk). The following day, the membrane was
incubated with primary antibody (in TBST  2% skim milk) for2ha troom
temperature and thereafter washed in TBST and incubated with horseradish
peroxidase–conjugated secondary antibody (Dako, Denmark) for1ha troom
temperature (TBST  2% skim milk). Immobilon Western (Millipore, Billerica,
MA) was used as a detection system. Bands were visualized using an Eastman
Kodak Image Station 2000MM. Bands were quantiﬁed using Kodak Molecular
Imaging Software version 4.0.3, and protein content was expressed in units
relative to control samples loaded on each gel.
Protein levels of the PDH-E1 subunit and phosphorylation of site 1 and 2
of PDH-E1 were determined using antibodies generated in sheep as previ-
ously described (12) and PDK4 protein by in-house–made antibodies gener-
ated in rabbit (26).
PDHa activity. The activity of PDHa (PDH in the active form) was deter-
mined as previously described (27–29) after homogenizing 10 mg muscle
tissue for 50 s in a glass homogenizer (Kontes) and quickly (10–15 s) freezing
the samples in liquid nitrogen. The PDHa activity was adjusted to total
creatine in each muscle sample.
Statistical analysis. Values presented are means  SE. Two-way ANOVA for
repeated measures was applied to evaluate the effect of exercise and trial (low
75% Wattmax 65% Wattmax
-2h 
Breakfast
• high fat = high FFA trial
• low fat = low FFA trial
0
Pre
10 min 20 min
Post ex
Muscle biopsies from both legs
Blood sampling
-15h
One leg 
glycogen 
depletion  
FIG. 1. A schematic overview of the experimental setup. Each subject completed the experiment on two separate days, with the only difference
being the breakfast consumed. Therefore, each subject completed both the high FFA and low FFA trial. Exercise (ex) was performed as
two-legged knee extensor exercise.
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The Student-Newman-Keuls post hoc test was used to locate differences.
Differences were considered signiﬁcant at P  0.05. Statistical calculations
were performed using SigmaStat Version 2.03.
RESULTS
Plasma FFA and insulin. The plasma FFA concentration
was in the high FFA trial 3.7-fold higher (P  0.05) at rest
and 2.5-fold higher (P  0.05) during exercise than in the
low FFA trial. In the high FFA trial, the plasma FFA
concentration was at 10 min of exercise reduced (P 
0.05) relative to pre-exercise. There was no difference in
plasma insulin levels between the trials or over time
(Table 1).
Muscle glycogen. Within each trial, muscle glycogen
concentration was in the LOW leg 46 and 37% of the
level in the CON leg before and after exercise, respectively
(P  0.05). Exercise lowered (P  0.05) muscle glycogen
in both legs in both trials (Fig. 2).
Muscle lactate. The muscle lactate concentration was
similar in CON and LOW leg before exercise in both trials
(Table 2). Muscle lactate concentration was 2.5-fold higher
(P  0.05) after exercise than before exercise in the low
FFA trial. Muscle lactate concentration was after exercise
in low FFA trial 2.4-fold higher (P  0.05) in CON leg than
in LOW leg. In addition the muscle lactate concentration
after exercise in CON leg was 1.1 fold higher (P  0.05) in
high FFA trial then low FFA trial.
Muscle glucose-6-phosphate. The muscle glucose-6-
phosphate concentration was similar in LOW and CON leg
before exercise in both trials. No changes were observed
over time in muscle glucose-6-phosphate concentration in
the LOW leg in either trial, whereas the glucose-6-phos-
phate concentration in the CON leg was increased (P 
0.05) 2.5-fold after exercise compared with before exer-
cise in both trials. The concentration of muscle glucose-6-
phosohate was 2.6-fold higher (P  0.05) in the CON leg
than LOW leg after exercise in the low FFA trial (Table 2).
Muscle glucose. The muscle glucose concentration was
similar in the LOW and CON leg before exercise in both
trials. No changes were observed over time in muscle
glucose concentration in the LOW leg in either trial,
whereas an approximately threefold increase (P  0.05)
was observed after exercise in the CON leg relative to
before exercise in both trials. The muscle glucose concen-
tration was 2.6-fold higher (P  0.05) in the CON leg than
in the LOW leg in both trials (Table 2).
PDHa activity. Before exercise, PDHa activity was simi-
lar in the two legs in both trials. Exercise increased (P 
0.05) the PDHa activity in both trials and legs. In the high
FFA trial, the increase in PDHa activity with exercise was
similar in the CON leg (3.8-fold) and LOW leg (3.7-fold; Fig.
4A). In the low FFA trial, exercise increased (P  0.05)
PDHa activity 5.7-fold in the CON leg and 5.1-fold in the
LOW leg, resulting in higher (P  0.05) PDHa activity level
in the CON than LOW leg after exercise.
TABLE 1
FFA and insulin before exercise, 10 min into exercise, and
immediately after 20 min of two-legged knee extensor exercise
High FFA Low FFA
Plasma FFA (mol/l)
Pre-exercise 714  142* 193  30
10 min exercise 497  61*† 188  24
Post-exercise 564  70* 223  29
Plasma insulin (pmol/l)
Pre-exercise 24  33 9  9
10 min exercise 13  11 9  3
Post-exercise 35  11 25  5
Data are means  SE. The experimental protocol was performed on
two occasions with either fat-rich (high FFA) or carbohydrate-rich
(low FFA) breakfast 2 h prior to the ﬁrst blood samples. *Signiﬁcant
difference between the trials, P  0.05. †Signiﬁcantly different from
pre-exercise, P  0.05.
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FIG. 2. Content of muscle glycogen in vastus lateralis before and after
20 min of two-legged knee extensor exercise (Ex). At the initiation of
this exercise, muscle glycogen was reduced in one leg (LOW leg) ()b y
one-legged exercise the day before (14 h prior) and high-fat diet
overnight, whereas the other leg (CON leg) (f) had normal glycogen
levels. The experimental protocol was performed on two occasions
with either fat-rich (high FFA) or carbohydrate-rich (low FFA) break-
fast 2 h before the ﬁrst biopsies. Values are means  SE. *Signiﬁcantly
different from CON at given time point and within given trial, P < 0.05.
†Signiﬁcantly different from Pre within given leg and trial.
TABLE 2
Muscle lactate, glucose-6-phosphate, and muscle glucose concen-
trations (in mmol/kg dry wt) in vastus lateralis muscle before and
immediately after 20 min of two-legged knee extensor exercise
High FFA Low FFA
CON LOW CON LOW
Muscle lactate
Pre-exercise 15  21 3  21 6  21 3  2
Post-exercise 35  10‡ 24  54 0  10† 17  2*
Glucose-6-
phosphate
Pre-exercise 1.0  0.2 0.8  0.2 0.8  0.1 0.7  0.2
Post-exercise 2.3  0.2† 1.1  0.2 2.3  0.5† 0.9  0.2*
Muscle glucose
Pre-exercise 1.8  0.3 1.8  0.3 1.7  0.3 1.8  0.3
Post-exercise 5.3  1.2† 2.1  0.3* 5.1  1.0† 1.9  0.4*
Data are means  SE. The LOW leg had reduced muscle glycogen
due to one-legged exercise the day before (14 h prior) and high-fat
diet overnight, whereas the prior nonexercised CON leg had normal
glycogen levels. The experimental protocol was performed on two
occasions with either fat-rich (high FFA) or carbohydrate-rich (low
FFA) breakfast 2 h before the ﬁrst biopsies. *Signiﬁcant difference
between CON and LOW, P  0.05. †Signiﬁcantly different from
pre-exercise, P  0.05. ‡Signiﬁcant difference between trials, P
0.05.
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exercise was 1.3-fold higher (P  0.05) in the low FFA trial
than in the high FFA trial.
PDK4 protein. The PDK4 protein content was higher
(P  0.05) in the LOW leg than in the CON leg before and
after exercise in both trials (1.5-fold higher [P  0.05]
level in the high FFA trial and 2.2-fold higher [P  0.05]
level in the low FFA trial). PDK4 protein content in the
CON leg was 19% lower (P  0.05) after exercise than
before in the high FFA trial, and PDK4 protein content in
the LOW leg was 21% lower (P  0.05) after exercise than
before in the low FFA trial (Fig. 3 and Fig. 4B). Before
exercise, PDK4 protein content in the CON leg was
approximately twofold higher (P  0.05) in the high FFA
trial than in the low FFA trial.
FIG. 3. Representative Western blots for PDK4 protein and for the
phosphorylation of PDH-P1 and PDH-P2 shown for the samples of one
subject. Ex, exercise.
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FIG. 4. A: Activity of PDH in the active form (PDHa activity). B: PDK4 protein expression. C: PDH-E1 site 1 phosphorylation. D: PDH-E1 site
2 phosphorylation in both vastus lateralis muscles before and immediately after 20 min of two-legged knee extensor exercise. At the initiation
of this exercise, muscle glycogen was reduced in one leg (LOW leg) () by one-legged exercise the day before (14 h prior) and high-fat diet
overnight, whereas prior non-exercised leg (CON leg) (f) had normal glycogen levels. The experimental protocol was performed on two occasions
with either fat-rich (high FFA) or carbohydrate-rich (low FFA) breakfast 2 h before the ﬁrst biopsies. Values are means  SE. *Signiﬁcantly
different from CON at given time point and within given trial, P < 0.05. †Signiﬁcantly different from Pre within given leg and trial, P < 0.05.
‡Signiﬁcantly different from low FFA trial, P < 0.05.
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protein content was the same in the two legs throughout
each protocol. The phosphorylation data are presented as
relative phosphorylation (normalized to the PDH-E1
content).
Exercise induced (P  0.05) a dephosphorylation of
PDH-P1 (to 20–45% of prelevel) and PDH-P2 (34–65% of
prelevel) in both trials and legs (Fig. 3 and Fig. 4C and D).
In the low FFA trial, phosphorylation on PDH-P1 and
PDH-P2 was greater (P  0.05) in the LOW leg than in the
CON leg at all time points, with 1.4-fold before exercise
and 2.8-fold after exercise, respectively.
No trial effect was apparent for PDH-P1 phosphorylation
in the CON leg. After exercise, phosphorylation on PDH-P2
was in the CON leg 2.9-fold higher (P  0.05) in the high
FFA trial than in the low FFA trial.
DISCUSSION
The main ﬁndings of the present study are that exercise
increases PDHa activity in human skeletal muscle despite
enhanced plasma FFA levels, but both reduced muscle
glycogen concentration and elevated plasma FFA levels
are associated with reduced exercise-induced PDH activa-
tion. In addition, the results support that the observed
relationship between these metabolic parameters and reg-
ulation of PDH may be mediated through effects on PDK4
expression before exercise.
The present ﬁnding that exercise increased the PDHa
activity at least threefold independent of differences in
muscle glycogen concentration, and despite enhanced
plasma FFA levels, demonstrates that mechanisms other
than muscle glycogen and plasma FFA dominate exer-
cise-induced PDH regulation in human skeletal muscle.
Increases in mitochondrial calcium levels are likely
important, since mitochondrial calcium concentration in-
creases during exercise (4,21) and calcium has been
shown to activate PDP1 leading to dephosphorylation and
activation of PDH (30). The impact of exercise on PDH
regulation in skeletal muscle unrelated to the metabolic
status of the cell and body may reﬂect that exercise can
overcome potential inhibition of carbohydrate utilization
present in resting skeletal muscle when circulating FFA
levels are increased (2). Thus, although there was no effect
of elevated FFA on PDHa activity at rest in the present
study, maybe due to the overnight high-fat diet in both
trials, elevated FFA levels have been shown to induce
insulin resistance (31,32), and individuals with enhanced
circulating FFA levels like type 2 diabetic subjects may
experience FFA-mediated insulin resistance at rest (33),
potentially in part because of FFA-induced downregula-
tion of PDH (1). Therefore, the observed upregulation of
PDHa activity by exercise despite elevated plasma FFA in
the present study in accordance with previous ﬁndings
(26,34,35) supports that a beneﬁcial effect of physical
activity may include that FFAs do not prevent exercise-
induced PDH activation.
However, the observation that the highest exercise-
induced PDHa activity and largest PDH dephosphorylation
were present when the muscle glycogen level was only
moderately reduced and when FFA remained close to
baseline levels (193 mol/l) indicates that metabolic fac-
tors do adjust the exercise-induced activation of PDH. In
addition, the smaller increase in PDHa activity and the
smaller decline in PDH dephosphorylation in response to
exercise when muscle glycogen was reduced or plasma
FFA concentration was elevated initially suggest that each
of these factors may modify exercise-induced PDH regu-
lation. Such an effect of FFA is in accordance with
previous studies, indicating that FFA downregulates PDHa
activity or increases PDH phosphorylation in rat (1) and
human (12) skeletal muscle at rest. A relation between
muscle glycogen levels and PDHa activity and PDH phos-
phorylation is in line with our previous ﬁnding that further
lowering of muscle glycogen during high-intensity exercise
was associated with reduced PDHa activity (17). Of notice
is also that the same degree of repression of PDHa activity
and PDH dephosphorylation changes was evident when
muscle glycogen was lowered to 268 mmol/kg dry wt or
plasma FFA was elevated to 714 mol/l, and when both
these changes were present simultaneously, no further
effect was found. Thus, the impact on PDH regulation
associated with low muscle glycogen and elevated plasma
FFA was not additive, which may suggest that a similar
underlying mechanism could be involved in exerting this
effect on PDHa activity.
The possibility that changes in PDK4 protein expression
may have mediated the observed association between
muscle glycogen and PDH regulation as well as between
plasma FFA and PDH regulation is supported by the
observation that the highest PDH activation and largest
dephosphorylation occurred in the leg and trial with
lowest PDK4 protein expression. The downregulation of
PDK4 protein content when plasma FFA was reduced by a
carbohydrate-rich breakfast in the present study supports
previous studies showing that an elevated FFA level is
associated with increased PDK4 expression (1,36). Al-
though plasma insulin was at basal level and similar in the
two trials when the pre-exercise biopsy was obtained, a
transient increase in plasma insulin in response to the
meal has without doubt occurred and cannot be excluded
to have had a contributing inﬂuence on the observed PDK4
expression, as previous studies have demonstrated that
insulin can regulate PDK4 expression (3,14). However,
PDK4 mRNA downregulation in human skeletal muscle is
typically not observed until after3ho finsulin infusion
(unpublished data, from our laboratory), and although
posttranscriptional regulation cannot be ruled out, these
ﬁndings do suggest that insulin changes elicited by the
meal unlikely have been important in the quick reduction
in PDK4 protein content observed in the present study.
The current ﬁnding that PDK4 protein content was
higher in the muscle with low glycogen than the control
muscle both before and after exercise and in both trials
indicates that reduced muscle glycogen levels could be an
initiating signal to increase PDK4 expression. These ﬁnd-
ings are in accordance with previous human studies
showing a similar association between lowered muscle
glycogen and regulation of PDK4 mRNA expression, but
changes in muscle glycogen was in these previous studies
accompanied by changes in plasma insulin and/or plasma
FFA (15,16). In the present study, however, the carbohy-
drate-rich breakfast meal in one trial ensured lowered
plasma FFA levels and normalized plasma insulin, leaving
only muscle glycogen different. Of notice is that the low
muscle glycogen leg had exercised intensively 14 h
before, and thus it cannot be ruled out that other exercise-
associated signals have initiated the induction of PDK4
expression in this muscle. In addition, we have recently
shown that PDK4 protein content is increased 6 h after a
prolonged exercise session, and although this change was
associated with reduced muscle glycogen, a decline in
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PDK4 protein expression after prolonged exercise in that
study (26). On the other hand, lowering of plasma FFA by
the carbohydrate-rich breakfast in the present study was
associated with a 50% reduction in PDK4 protein content
in the control leg but not in the low glycogen leg, support-
ing that reduced muscle glycogen may indeed have in-
duced PDK4 protein expression. Thus, taken together, the
association between changes in muscle glycogen and
PDK4 protein as well as between plasma FFA levels and
PDK4 protein content supports that PDK4 expression may
be regulated by each of these metabolic parameters.
Moreover, the association between PDK4 protein content
and both PDH phosphorylation and PDHa activity also
supports that such PDK4 expression changes may have a
functional role in regulating substrate utilization in human
skeletal muscle to match availability.
The lowering of PDK4 protein content just 2 h after the
carbohydrate-rich meal, and the reduction in response to
20 min of exercise, clearly shows that regulation of PDK4
protein content is fast. To our knowledge, no previous
studies have reported such quick regulation of PDK4
protein content in skeletal muscle, although changes have
been reported in PDK4 protein after 48 h of fasting in rats
(14) and 1 day of high-fat diet in humans (37), and we
recently have shown an upregulation of PDK4 protein 6 h
after a single exercise session (26).
Glycolytic ﬂux has been suggested to be one factor
regulating PDH and hence the ﬂux through the pyruvate
dehydrogenase complex (29,35,38). Based on measure-
ments of muscle glucose and muscle glucose-6-phosphate
concentrations, the current ﬁndings may suggest that
glycolytic ﬂux did not entirely determine the PDH activity
during exercise. Thus, the clear differences in exercise-
induced muscle glucose-6-phosphate and muscle glucose
responses in the normal and the low muscle glycogen
muscles in the high FFA trial were not associated with
differences in PDH regulation, and despite similar muscle
glucose-6-phosphate and muscle glucose levels in the
normal glycogen leg in the two trials, PDHa activity was
higher in the low FFA trial than in the high FFA trial. Such
interpretation is supported by the observation that lower
glycogen utilization in the low glycogen muscle than in the
normal glycogen muscle occurred without inﬂuence on
PDH regulation in the high FFA trial. But at the same time,
the present data are also consistent with the previous
indications (29,36,37) that PDH activation plays a role in
determining the balance between glycolytic/glycogenolytic
ﬂux and oxidation. Hence, accumulation of glycolytic
intermediates may depend on how well glycolytic ﬂux and
PDH activity match, and the lack of accumulation of
intermediates in the low leg in both trials may reﬂect a
balanced glycolytic ﬂux and PDH activity, whereas glyco-
lytic ﬂux may have exceeded PDH activity in the CON leg,
leading to accumulation of glucose-6-phosphate.
In conclusion, muscle glycogen and plasma FFAs mod-
ify exercise-induced PDH regulation in human skeletal
muscle in a nonadditive manner, which might be through
glycogen and FFA-mediated regulation of PDK4 expres-
sion. However, of notice is that marked exercise-induced
activation of PDH was still present when plasma FFA was
elevated, which suggests that beneﬁcial effects of physical
activity include that exercise overrules FFA-mediated in-
hibition of carbohydrate oxidation.
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